VISIPAQUE 320 Rx
Generic Name and Formulations:
Iodixanol 652mg/mL; soln for inj; contains sodium 1.11mg/mL, organically bound iodine 320mg/mL; preservative-free.
Indications for VISIPAQUE 320:
Intra-arterial: Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. IV: CECT imaging of the head and body, and excretory urography.
Usual single doses: Intra-arterial: Arteriography: Carotid arteries: 10–14mL; Vertebral arteries: 10–12mL (max 175mL); Right coronary artery: 3–8mL; Left coronary artery: 3–10mL; Left ventricle: 20–45mL (max 200mL); Renal arteries: 8–18mL; Aortography: 30–70mL; Major branches of aorta: 10–70mL; Aortofemoral runoffs: 20–90mL; Peripheral arteries: 15–30mL (max 250mL). Intra-arterial Digital Subtraction Angiography: Carotid or vertebral arteries: 5–8mL (max 175mL); Aortography: 10–50mL; Major branches of aorta: 2–10mL; Aortofemoral runoffs: 6–15mL; Peripheral arteries: 3–15mL (max 250mL). IV: CECT of head or body: 75–150mL bolus or 100–150mL infusion; max 150mL. Excretory urography (normal renal function): 1mL/kg; max 100mL.
<1yr: not recommended. ≥1yr: Intra-arterial for cerebral, cardiac chambers and related major arteries, and visceral studies: 1–2mL/kg; max 4mL/kg.
Intrathecal use. Children: Prolonged fasting and laxative administration before Visipaque injection.
Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Homocystinuria: avoid. Severe renal impairment. Combined renal and hepatic disease. Combined renal and cardiac disease. CHF. Diabetes. Severe thyrotoxicosis. Myelomatosis. Anuria. Pheochromocytoma. Homozygous sickle cell disease. Immune deficiency disorder. Maintain adequate hydration. Avoid extravasation. Children: asthma, cyanotic and acyanotic heart disease, CHF, serum creatinine >1.5mg/dL, immature renal function, dehydration: increased risk of adverse effects. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Radiographic contrast medium.
Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for up to 16 days.
Rash, erythema, pruritus, scotoma; thromboembolic events, hypersensitivity reactions, others.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC